Dr. Lee on the Impact of Immunotherapy in Head and Neck Cancer

Nancy Y. Lee, MD
Published: Tuesday, Jun 13, 2017



Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are both FDA-approved for the treatment of patients with head and neck cancer. The impact of these immunotherapy agents, says Lee, is that patients are living longer—whereas in the past they would have succumbed to their disease.

After immunotherapy is given, says Lee, the makeup of the patient is different—allowing some to respond to other types of therapies.
 
SELECTED
LANGUAGE


Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are both FDA-approved for the treatment of patients with head and neck cancer. The impact of these immunotherapy agents, says Lee, is that patients are living longer—whereas in the past they would have succumbed to their disease.

After immunotherapy is given, says Lee, the makeup of the patient is different—allowing some to respond to other types of therapies.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x